This Article Full Text Full Text (PDF) All Versions of this Article: 36/3/649    most recent 01.STR.0000155731.92786.e9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asselbergs, F. W. Search for Related Content PubMed PubMed Citation Articles by Asselbergs, F. W. Related Collections Primary prevention Endothelium/vascular type/nitric oxide Other diagnostic testing Risk Factors Other imaging

(Stroke. 2005;36:649.)
© 2005 American Heart Association, Inc.

Original Contributions

Effects of Fosinopril and Pravastatin on Carotid Intima-Media Thickness in Subjects With Increased Albuminuria

Folkert W. Asselbergs, MD, PhD; Arie M. van Roon, PhD; Hans L. Hillege, MD, PhD; Paul E. de Jong, MD, PhD; Reinold O.B. Gans, MD, PhD; Andries J. Smit, MD, PhD Wiek H. van Gilst, PhD on behalf of the PREVEND IT Investigators

From the Department of Clinical Pharmacology (F.W.A., W.H.v.G.), University of Groningen, Groningen, the Netherlands; the Department of Internal Medicine (A.M.v.R, R.O.B.G., A.J.S.), Trial Coordination Center (H.L.H.), and the Department of Nephrology (P.E.d.J.), University Hospital Groningen, Groningen, the Netherlands.

Correspondence to Dr Folkert W. Asselbergs, Department of Clinical Pharmacology, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, the Netherlands. E-mail f.w.asselbergs{at}thorax.azg.nl

Background and Purpose— Elevated urinary albumin excretion (UAE) is associated with an increased carotid intima-media thickness (IMT). Because angiotensin-converting enzyme inhibitors as well as statins have been shown to lower UAE and the progression of IMT, we assessed the effects of fosinopril and pravastatin on carotid IMT in subjects with an increased UAE (15 to 300 mg/24 h).

Methods— IMT was measured at the posterior wall of the left common carotid artery using radio-frequency signal analysis obtained by M-mode ultrasonography. 642 subjects were double-blind randomized to fosinopril 20 mg or matching placebo and to pravastatin 40 mg or matching placebo and were available for intention-to-treat analysis.

Results— Mean age was 51±11 years, 65% were male, the median UAE was 22.5 (15.5 to 40.8) mg/24 h, and the mean IMT at baseline was 0.77±0.18 mm. The overall progression rate of IMT in 4 years was 0.037±0.006 mm. No significant difference in IMT progression was found between fosinopril, pravastatin, or matching placebo. IMT after 4 years was predicted by IMT at baseline, age, gender, pulse pressure, and low-density lipoprotein cholesterol levels. Furthermore, a higher incidence of clinical events was observed in subjects with an IMT >1 mm after a mean follow-up of 46±7 months (hazard ratio, 3.13; 95% confidence interval, 1.59 to 6.16; P=0.001).

Conclusions— In subjects with an increased UAE, treatment with fosinopril and pravastatin showed no significant effect on carotid IMT. Furthermore, an IMT <1 mm at baseline is an important indicator for event-free survival.

Key Words: ACE inhibitors • albuminuria • carotid arteries • controlled clinical trials • statins

This article has been cited by other articles:

				Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]

				H. Yanai, H. Yoshida, Y. Tomono, and N. Tada Atherosclerosis imaging in statin intervention trials QJM, May 1, 2007; 100(5): 253 - 262. [Full Text] [PDF]

				M. L. Bots, D. Baldassarre, A. Simon, E. de Groot, D. H. O'Leary, W. Riley, J. J. Kastelein, and D. E. Grobbee Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur. Heart J., February 2, 2007; 28(4): 398 - 406. [Abstract] [Full Text] [PDF]

				J.-G. Wang, J. A. Staessen, Y. Li, L. M. Van Bortel, T. Nawrot, R. Fagard, F. H. Messerli, and M. Safar Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials Stroke, July 1, 2006; 37(7): 1933 - 1940. [Abstract] [Full Text] [PDF]

				F. W. Asselbergs and W. H. van Gilst Letters to the Editor: Urinary Albumin Excretion and Carotid Intima-Media Thickness Hypertension, December 1, 2005; 46(6): e20 - e20. [Full Text] [PDF]

				C. A. Geluk, F. W. Asselbergs, H. L. Hillege, S. J.L. Bakker, P. E. de Jong, F. Zijlstra, and W. H. van Gilst Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial Eur. Heart J., July 1, 2005; 26(13): 1314 - 1320. [Abstract] [Full Text] [PDF]

				D. de Zeeuw Albuminuria, Just a Marker for Cardiovascular Disease, Or Is It More? J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1883 - 1885. [Full Text] [PDF]